| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Blinded and uniform cause of death verification in a lung cancer CT screening trial
DOI: 10.1016/j.lungcan.2012.04.018
Abstract: Disease-specific mortality is the final outcome of a lung cancer screening trial, therefore cause of death verification is crucial. The use of death certificates for this purpose is debated ...
|
N. Horeweg,
R.J. van Klaveren,
H.J.M. Groen,
J.-W.J. Lammers,
C. Weenink,
K. Nackaerts,
W. Mali,
M. Oudkerk,
H.J. de Koning
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 May 2012 |
|
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation
DOI: 10.1016/j.lungcan.2012.04.012
Abstract: Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations in non-small cell lung cancer (NSCLC) are mutually exclusive. However, several exception...
|
June Koo Lee,
Tae Min Kim,
Youngil Koh,
Se-Hoon Lee,
Dong-Wan Kim,
Yoon-Kyung Jeon,
Doo Hyun Chung,
Seok-Chul Yang,
Young Tae Kim,
Young-Whan Kim,
Dae Seog Heo,
Yung-Jue Bang
et al.
|
Short communication
(In Press Corrected Proof)
|
23 May 2012 |
|
New vision, new hope: Building momentum in NSCLC
DOI: 10.1016/j.lungcan.2012.05.090
|
|
Other contents
(In Press Corrected Proof)
|
21 May 2012 |
|
Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study
DOI: 10.1016/j.lungcan.2012.04.015
Abstract: Few studies have examined the association between non-steroidal anti-inflammatory drug (NSAID) use and risk of small cell lung cancer (SCLC); among them, findings are mixed. Recently, we fou...
|
Theodore M. Brasky,
Christina S. Baik,
Christopher G. Slatore,
John D. Potter,
Emily White
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy
DOI: 10.1016/j.lungcan.2012.04.016
Abstract: Background: First-line platinum-based chemotherapy is currently considered the standard treatment for unresectable non-small cell lung cancer (NSCLC). However, resistance to platinum-based c...
|
Seok-Hyun Kim,
Gyeong-Won Lee,
Min Jeong Lee,
Yu Ji Cho,
Yi Yeong Jeong,
Ho-Cheol Kim,
Jong Duk Lee,
Young Sil Hwang,
In-Suk Kim,
Suee Lee,
Sung Yong Oh
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials
DOI: 10.1016/j.lungcan.2012.04.017
Abstract: Introduction: We sought to estimate life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer (NSCLC). Methods: We searched for randomized first-li...
|
B.E. Kiely,
M. Alam,
P. Blinman,
M.H.N. Tattersall,
M.R. Stockler
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC)
DOI: 10.1016/j.lungcan.2012.04.011
Abstract: We hypothesized that the increased percentages of Regulatory T (Treg) cells, as well as over expression of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) by lymphocyte subsets might be associated...
|
Nasrollah Erfani,
Shayesteh Mofakhami Mehrabadi,
Mohammad Ali Ghayumi,
Mohammad Reza Haghshenas,
Zahra Mojtahedi,
Abbas Ghaderi,
Davar Amani
et al.
|
Full-length article
(In Press Corrected Proof)
|
21 May 2012 |
|
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
DOI: 10.1016/j.lungcan.2012.04.013
Abstract: The most serious adverse reaction associated with treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is drug-induced interstitial lung disease (ILD). Beca...
|
Yosuke Togashi,
Katsuhiro Masago,
Yasuhiro Hamatani,
Yuichi Sakamori,
Hiroki Nagai,
Young Hak Kim,
Michiaki Mishima
et al.
|
Short communication
(In Press Corrected Proof)
|
14 May 2012 |
|
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?
DOI: 10.1016/j.lungcan.2012.04.009
Abstract: Background: There is controversy regarding palliative chemotherapy for large cell neuroendocrine carcinoma (LCNEC). We evaluated whether advanced LCNEC should be treated similarly to small c...
|
Jong-Mu Sun,
Myung-Ju Ahn,
Jin Seok Ahn,
Sang-Won Um,
Hojoong Kim,
Hong Kwan Kim,
Young Soo Choi,
Joungho Han,
Jhingook Kim,
O Jung Kwon,
Young Mog Shim,
Keunchil Park
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China
DOI: 10.1016/j.lungcan.2012.04.014
Abstract: Introduction: Treatment choice for NSCLC in China has not previously been reported. This paper explores the clinical practice and adherence to treatment guidelines for NSCLC. Methods: A spec...
|
Cong Xue,
Zhihuang Hu,
Wei Jiang,
Yuanyuan Zhao,
Fei Xu,
Yan Huang,
Hongyun Zhao,
Jingxun Wu,
Yang Zhang,
Liping Zhao,
Jing Zhang,
Likun Chen,
Li Zhang
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 May 2012 |
|
Prognostic impact of nestin expression in resected large cell neuroendocrine carcinoma of the lung
DOI: 10.1016/j.lungcan.2012.03.025
Abstract: Background: Large cell neuroendocrine carcinoma (LCNEC) of the lung is categorized as a high-grade neuroendocrine carcinoma with an aggressive clinical behavior. Nestin is a class VI interme...
|
Shinichiro Ryuge,
Yuichi Sato,
Shi Xu Jiang,
Guoqin Wang,
Toshihide Matsumoto,
Ken Katono,
Hayato Inoue,
Akira Iyoda,
Yukitoshi Satoh,
Hirokuni Yoshimura,
Noriyuki Masuda
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 May 2012 |
|
Characterization of vitamin D receptor (VDR) in lung adenocarcinoma
DOI: 10.1016/j.lungcan.2012.04.010
Abstract: Purpose: The anti-proliferative effects of 1α,25-dihydroxyvitamin D3 (1,25-D3, calcitriol, the active form of vitamin D) are mediated by the nuclear vitamin D receptor (VDR). In the present ...
|
So Hee Kim,
Guoan Chen,
Amanda N. King,
Chae Kyung Jeon,
Paul J. Christensen,
Lili Zhao,
Robert U. Simpson,
Dafydd G. Thomas,
Thomas J. Giordano,
Dean E. Brenner,
Bruce Hollis,
David G. Beer,
Nithya Ramnath
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 May 2012 |
|
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer
DOI: 10.1016/j.lungcan.2012.03.009
Abstract: Background: Inhibition of angiogenesis may be effective in the treatment of small-cell lung cancer (SCLC). Sunitinib, an oral agent that inhibits the VEGF signaling pathway, may delay progre...
|
David R. Spigel,
F. Anthony Greco,
Mark S. Rubin,
Dianna Shipley,
Dana S. Thompson,
Eric T. Lubiner,
Janice F. Eakle,
Raven Quinn,
Howard A. Burris,
John D. Hainsworth
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 May 2012 |
|
Clinical and molecular analysis of synchronous double lung cancers
DOI: 10.1016/j.lungcan.2012.04.003
Abstract: Background: Since multiple lung cancer treatment strategies differ, it is essential for clinicians to be able to distinguish between separate primary lesions and metastasis. In the present s...
|
Junichi Arai,
Tomoshi Tsuchiya,
Masahiro Oikawa,
Koji Mochinaga,
Tomayoshi Hayashi,
Koh-ichiro Yoshiura,
Kazuhiro Tsukamoto,
Naoya Yamasaki,
Keitaro Matsumoto,
Takuro Miyazaki,
Takeshi Nagayasu
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 May 2012 |
|
ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy
DOI: 10.1016/j.lungcan.2012.04.005
Abstract: Purpose: To utilize a novel circulating tumor cell (CTC) technology to quantify ERCC1 expression on CTCs and determine whether ERCC1 expression levels predict efficacy of platinum-based chem...
|
Millie Das,
Jonathan W. Riess,
Paul Frankel,
Erich Schwartz,
Robyn Bennis,
H. Ben Hsieh,
Xiohe Liu,
Janey C. Ly,
Lisa Zhou,
Jorge J. Nieva,
Heather A. Wakelee,
Richard H. Bruce
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 May 2012 |
|
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer
DOI: 10.1016/j.lungcan.2012.04.008
Abstract: Purpose: Lung cancer is the most common cause of cancer death. A cumulative prognostic score based on C-reactive protein and albumin, termed the Glasgow Prognostic Score (GPS), indicates the...
|
Ioannis Gioulbasanis,
Athanasios Pallis,
Panagiotis J. Vlachostergios,
Alexandros Xyrafas,
Zoe Giannousi,
Isidora-Eleni Perdikouri,
Michalitsa Makridou,
Dionysia Kakalou,
Vassilios Georgoulias
et al.
|
Full-length article
(In Press Corrected Proof)
|
01 May 2012 |
|
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
DOI: 10.1016/j.lungcan.2012.03.019
Abstract: Background: Maintenance therapy is a new treatment paradigm for advanced non-small cell lung cancer (NSCLC). We conducted a meta-analysis of randomized studies with single agent maintenance ...
|
Madhusmita Behera,
Taofeek K. Owonikoko,
Zhengjia Chen,
Scott A. Kono,
Fadlo R. Khuri,
Chandra P. Belani,
Suresh S. Ramalingam
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma
DOI: 10.1016/j.lungcan.2012.04.004
Abstract: Background: EGFR mutation status is the best predictor of response to tyrosine kinase inhibitors (TKIS) in primary lung adenocarcinoma. Approximately 70% of lung cancers are diagnosed in adv...
|
Adnan Hasanovic,
Daphne Ang,
Andre L. Moreira,
Maureen F. Zakowski
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Loss of heterozygosity of the Mutated in Colorectal Cancer gene is not associated with promoter methylation in non-small cell lung cancer
DOI: 10.1016/j.lungcan.2012.04.001
Abstract: ‘Mutated in Colorectal Cancer’ (MCC) is emerging as a multifunctional protein that affects several cellular processes and pathways. Although the MCC gene is rarely mutated in colorectal canc...
|
Pirooz Poursoltan,
Nicola Currey,
Laurent Pangon,
Christa van Kralingen,
Christina I. Selinger,
Annabelle Mahar,
Wendy A. Cooper,
Catherine W. Kennedy,
Brian C. McCaughan,
Ronald Trent,
Maija R.J. Kohonen-Corish
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases
DOI: 10.1016/j.lungcan.2012.03.028
Abstract: Introduction: The Graded Prognostic Assessment (GPA) provides prognostic classification for patients with brain metastases (BM), based on Radiation Therapy Oncology Group (RTOG) data. Recent...
|
Susan Guo,
Chandana A. Reddy,
Samuel T. Chao,
John H. Suh,
Gene H. Barnett,
Michael A. Vogelbaum,
Gregory M. Videtic
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Expression and prognostic significance of centromere protein A in human lung adenocarcinoma
DOI: 10.1016/j.lungcan.2012.04.007
Abstract: Background: Centromere protein A (CENP-A), one of the fundamental components of the human active kinetochore, is frequently upregulated in many cancers and plays important roles in cell cycl...
|
Qing Wu,
Yi-Ming Qian,
Xiang-Li Zhao,
Shou-Mei Wang,
Xiao-Jun Feng,
Xin-Fang Chen,
Shu-Hui Zhang
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma
DOI: 10.1016/j.lungcan.2012.04.002
Abstract: Angiolymphatic invasion (ALI), representing lymphatic invasion (Ly) and intratumoral vascular invasion (V), is considered to be a useful prognostic factor for pathological stage I non-small ...
|
Tatsuya Kato,
Keidai Ishikawa,
Masato Aragaki,
Masaaki Sato,
Kenzo Okamoto,
Tetsuya Ishibashi,
Mitsuhito Kaji
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 April 2012 |
|
Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure
DOI: 10.1016/j.lungcan.2012.03.024
Abstract: The prognosis of lung cancer is poor due to late diagnosis, the lack of established screening programs, and the paucity of early biomarkers for high-risk populations. Plasma proteome analysi...
|
Annina Rostila,
Anne Puustinen,
Tuula Toljamo,
Katri Vuopala,
Irmeli Lindström,
Tuula A. Nyman,
Panu Oksa,
Tapio Vehmas,
Sisko L. Anttila
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 April 2012 |
|
Prospective study of transarterial infusion of docetaxel and cisplatin to treat non-small-cell lung cancer in patients contraindicated for standard chemotherapy
DOI: 10.1016/j.lungcan.2012.04.006
Abstract: Our previous retrospective study indicated a good response rate of non-small-cell lung carcinoma (NSCLC) to transarterial infusion chemotherapy, but the precise effect remains unresolved. Th...
|
Masanori Nakanishi,
Yoshimasa Yoshida,
Toshiki Natazuka
|
Full-length article
(In Press Corrected Proof)
|
26 April 2012 |
|
Use of erlotinib throughout pregnancy: A case-report of a patient with metastatic lung adenocarcinoma
DOI: 10.1016/j.lungcan.2012.03.026
Abstract: The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebr...
|
Giovanna Rivas,
Nestor Llinás,
Carlos Bonilla,
Juan Rubiano,
Javier Cuello,
Natalia Arango
et al.
|
Short communication
(In Press Corrected Proof)
|
25 April 2012 |
|
Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer
DOI: 10.1016/j.lungcan.2012.03.027
Abstract: Background: Compared to well-known function of cyclin D1 in lung cancer, the role of cyclin D2 is not clear. This study was aimed at understanding the clinicopathological significance of cyc...
|
Eunkyung Ko,
Yujin Kim,
Seong-Eun Park,
Eun Yoon Cho,
Jungho Han,
Young Mog Shim,
Joobae Park,
Duk-Hwan Kim
et al.
|
Full-length article
(In Press Corrected Proof)
|
25 April 2012 |
|
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
DOI: 10.1016/j.lungcan.2012.03.011
Abstract: Introduction: Treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors or chemotherapy have shown improved survival outcomes in East Asian, never-smoker patients wit...
|
Myung-Ju Ahn,
James Chih-Hsin Yang,
Jun Liang,
Jin-Hyoung Kang,
Qingyu Xiu,
Yuh-Min Chen,
Julie Michelle Blair,
Guangbin Peng,
Carlos Linn,
Mauro Orlando
et al.
|
Full-length article
(In Press Corrected Proof)
|
25 April 2012 |
|
Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients
DOI: 10.1016/j.lungcan.2012.03.016
Abstract: Background and purpose: Cisplatin is the major agent in the standard first-line chemotherapy for NSCLC. However, only a small portion of patients achieve a tumor response to cisplatin-based ...
|
Peng Kuang,
Caicun Zhou,
Xuefei Li,
Shengxiang Ren,
Bing Li,
Yongsheng Wang,
Jiayu Li,
Liang Tang,
Jie Zhang,
Yinmin Zhao
et al.
|
Full-length article
(In Press Corrected Proof)
|
25 April 2012 |
|
EGFR mutations as a predictive marker of cytotoxic chemotherapy
DOI: 10.1016/j.lungcan.2012.03.020
Abstract: Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) are important predictive markers for the response to EGFR-tyrosine kinase inhibitors (EGFR...
|
Jin Hyun Park,
Se-Hoon Lee,
Bhumsuk Keam,
Tae Min Kim,
Dong-Wan Kim,
Seok-Chul Yang,
Young Whan Kim,
Dae Seog Heo
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
EBUS-TBNA in patients presented with superior vena cava syndrome
DOI: 10.1016/j.lungcan.2012.03.015
Abstract: Introduction: Expedient pathological diagnosis is crucial in selection of appropriate treatment in patients presented with superior vena cava syndrome (SVCS). The performance and safety of e...
|
Matthew K. Wong,
Terence C. Tam,
David C. Lam,
Mary S. Ip,
James C. Ho
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 April 2012 |
|
Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients
DOI: 10.1016/j.lungcan.2012.03.023
Abstract: Background: Cisplatin toxicity severely obstacles successful chemotherapy in lung cancer patients. Cisplatin uptake is considered as one of the major factors contributing to the side effects...
|
Xiaojing Xu,
Huayi Ren,
Boting Zhou,
Yingchun Zhao,
Ruixia Yuan,
Rui Ma,
Honghao Zhou,
Zhaoqian Liu
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 April 2012 |
|
Risk factors for radiation-induced lung toxicity in patients with non-small cell lung cancer who received postoperative radiation therapy
DOI: 10.1016/j.lungcan.2012.03.017
Abstract: Background and purpose: To evaluate the risk factors for radiation-induced lung toxicity (RILT) from post-operative radiation therapy (PORT) in patients with non-small cell lung cancer (NSCL...
|
Lujun Zhao,
Wei Ji,
Guangfei Ou,
Jima Lv,
Jun Liang,
Qinfu Feng,
Zongmei Zhou,
Luhua Wang,
Weibo Yin
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 April 2012 |
|
Perineal and colonic metastases in two cases of malignant mesothelioma
DOI: 10.1016/j.lungcan.2012.03.021
Abstract: Two patients with rare sites of metastatic pleural mesothelioma are presented and the literature on similar cases is examined. One patient developed colonic metastases from a sarcomatoid mes...
|
Bhajneek Grewal,
Gordon Reid,
Hannah Lord
|
Short communication
(In Press Corrected Proof)
|
16 April 2012 |
|
Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
DOI: 10.1016/j.lungcan.2012.03.010
Abstract: The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved overall survival in the first-line treatment of patients with advanced non-small cell lung c...
|
R. Pirker,
J.R. Pereira,
A. Szczesna,
J. von Pawel,
M. Krzakowski,
R. Ramlau,
I. Vynnychenko,
K. Park,
W.E.E. Eberhardt,
F. de Marinis,
S. Heeger,
T. Goddemeier,
K.J. O’Byrne,
U. Gatzemeier
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 April 2012 |
|
Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer
DOI: 10.1016/j.lungcan.2012.03.007
Abstract: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and relatively resistant to chemotherapy. The most prevalent molecular abnormality in NSCLC is the overactivation of...
|
Heather Male,
Vijay Patel,
Mark A. Jacob,
Emma Borrego-Diaz,
Kun Wang,
Derek A. Young,
Amanda L. Wise,
Chao Huang,
Peter Van Veldhuizen,
Amy O’Brien-Ladner,
Stephen K. Williamson,
Sarah A. Taylor,
Ossama Tawfik,
Tuba Esfandyari,
Faris Farassati
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 April 2012 |
|
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma
DOI: 10.1016/j.lungcan.2012.03.008
Abstract: Malignant pleural mesothelioma (MPM) is resistant to conventional treatments. Novel, targeted treatments are hampered by the relative lack of MPM-associated tumour antigens. The aim of this ...
|
Saly Al-Taei,
Josephine Salimu,
Jason F. Lester,
Seamus Linnane,
Madusha Goonewardena,
Richard Harrop,
Malcolm D. Mason,
Zsuzsanna Tabi
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 April 2012 |
|
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study
DOI: 10.1016/j.lungcan.2012.03.012
Abstract: Maintenance therapy, commenced immediately after the completion of first-line chemotherapy, is a promising strategy for improving treatment outcomes in patients with non-small-cell lung canc...
|
Yi-Long Wu,
Joo-Hang Kim,
Keunchil Park,
Adel Zaatar,
Gaëlle Klingelschmitt,
Christina Ng
et al.
|
Full-length article
(In Press Corrected Proof)
|
11 April 2012 |
|
Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy
DOI: 10.1016/j.lungcan.2012.03.018
Abstract: The presence of fusion genes between the anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) genes is useful for determining appropriate molecular-ta...
|
Nobuhiro Kanaji,
Shuji Bandoh,
Tomoya Ishii,
Akira Tadokoro,
Naoki Watanabe,
Takayuki Takahama,
Reiji Haba,
Osamu Imataki,
Hiroaki Dobashi,
Takuya Matsunaga
et al.
|
Full-length article
(In Press Corrected Proof)
|
11 April 2012 |
|
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group
DOI: 10.1016/j.lungcan.2012.03.002
Abstract: Objective: We examined the prognosis of patients with leptomeningeal metastasis (LM) from non-small cell lung cancer (NSCLC) and that stratified by epidermal growth factor receptor (EGFR) mu...
|
Shigeki Umemura,
Kazuya Tsubouchi,
Hiroshige Yoshioka,
Katsuyuki Hotta,
Nagio Takigawa,
Keiichi Fujiwara,
Naokatsu Horita,
Yoshihiko Segawa,
Noboru Hamada,
Ichiro Takata,
Hiromichi Yamane,
Haruhito Kamei,
Katsuyuki Kiura,
Mitsune Tanimoto
et al.
|
Full-length article
(In Press Corrected Proof)
|
10 April 2012 |
|
Thymoma and solid-organ transplantation
DOI: 10.1016/j.lungcan.2012.03.014
Abstract: Solid-organ-transplant recipients are at high risk of developing cancer, including thoracic malignancies. Herein, we report on two cases of thymoma in solid-organ recipients. One case was a ...
|
Nicolas Guibert,
Laurent Brouchet,
Isabelle Rouquette,
Alain Didier,
Lionel Rostaing,
Nassim Kamar,
Julien Mazieres
et al.
|
Short communication
(In Press Corrected Proof)
|
09 April 2012 |
|
The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)
DOI: 10.1016/j.lungcan.2012.03.003
Abstract: Background: In selected patients with advanced non-small cell lung cancer (NSCLC) the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor (TKI) gefitinib (IRESSA) shows respons...
|
Sandra Gottschling,
Esther Herpel,
Wilfried E.E. Eberhardt,
David F. Heigener,
Jürgen R. Fischer,
Claus-Henning Köhne,
Cornelius Kortsik,
Thomas Kuhnt,
Thomas Muley,
Michael Meister,
Helge G. Bischoff,
Peter Klein,
Ines Moldenhauer,
Philipp A. Schnabel,
Michael Thomas,
Roland Penzel
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 April 2012 |
|
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
DOI: 10.1016/j.lungcan.2012.03.013
Abstract: Introduction: The fusion oncogene of echinoderm microtubule-associated protein like 4 (EML4) and anaplastic lymphoma kinase (ALK) defines a new molecular subset of non-small-cell lung cancer...
|
Takayuki Fukui,
Yasushi Yatabe,
Yoshihisa Kobayashi,
Kenji Tomizawa,
Simon Ito,
Shunzo Hatooka,
Keitaro Matsuo,
Tetsuya Mitsudomi
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 April 2012 |
|
VEGF and sVEGFR-1 in malignant pleural effusions: Association with survival and pleurodesis outcomes
DOI: 10.1016/j.lungcan.2012.03.006
Abstract: VEGF is a key mediator of tumour growth and metastasis and is considered central to the formation of exudative pleural effusions. This study examined the relationship between levels of VEGF ...
|
C.E. Hooper,
K.T. Elvers,
G.I. Welsh,
A.B. Millar,
N.A. Maskell
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 April 2012 |
|
SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors
DOI: 10.1016/j.lungcan.2012.02.017
Abstract: Purpose: Lung cancer survivors report the lowest quality of life relative to other cancer survivors. Pain is one of the most devastating, persistent, and incapacitating symptoms for lung can...
|
Sarah M. Rausch,
Brian D. Gonzalez,
Matthew M. Clark,
Christi Patten,
Sara Felten,
Heshan Liu,
Yafei Li,
Jeff Sloan,
Ping Yang
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer
DOI: 10.1016/j.lungcan.2012.03.005
Abstract: There is evidence that aspirin and non-aspirin non-steroidal anti-inflammatory drug (NSAID) have anti-carcinogenic properties, but their effect on lung cancer, in particular in never-smokers...
|
Wei-Yen Lim,
Khoon Leong Chuah,
Philip Eng,
Swan Swan Leong,
Elaine Lim,
Tow Keang Lim,
Alan Ng,
Wee Teng Poh,
Augustine Tee,
Ming Teh,
Agus Salim,
Adeline Seow
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 April 2012 |
|
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
DOI: 10.1016/j.lungcan.2012.03.004
Abstract: Fluorescence in situ hybridization (FISH) is currently used to detect non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) gene rearrangement, who are candidates...
|
Heae Surng Park,
June Koo Lee,
Dong-Wan Kim,
Kimary Kulig,
Tae Min Kim,
Se-Hoon Lee,
Yoon-Kyung Jeon,
Doo Hyun Chung,
Dae Seog Heo
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 April 2012 |
|
Generalisability of the results of the Dutch–Belgian randomised controlled lung cancer CT screening trial (NELSON): Does self-selection play a role?
DOI: 10.1016/j.lungcan.2012.02.021
Abstract: The degree of self-selection in the Dutch–Belgian randomised controlled lung cancer screening trial (NELSON) was determined to assess the generalisability of the study results. 335,441 (main...
|
C.M. van der Aalst,
C.A. van Iersel,
R.J. van Klaveren,
F.J.M. Frenken,
J. Fracheboud,
S.J. Otto,
P.A. de Jong,
M. Oudkerk,
H.J. de Koning
et al.
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
DOI: 10.1016/j.lungcan.2012.02.022
Abstract: Background: Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm with elevated AKT/mTOR activity. We aimed to identify the expression and phosphorylation status of PTEN, PI3K...
|
S. Cedrés,
M.A. Montero,
P. Martinez,
A. Martinez,
V. Rodríguez-Freixinós,
D. Torrejon,
A. Gabaldon,
M. Salcedo,
S. Ramon y Cajal,
E. Felip
et al.
|
Full-length article
(In Press Corrected Proof)
|
29 March 2012 |
|
Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC)
DOI: 10.1016/j.lungcan.2012.03.001
Abstract: Purpose: To identify potential biomarkers for the prognosis of non-small cell lung cancer (NSCLC) patients by using bronchial brushing specimens. Methods: The expression of MCM7, Ki67 and EG...
|
Yi-Zhen Liu,
Yan-Yi Jiang,
Jia-Jie Hao,
Shan-Shan Lu,
Tong-Tong Zhang,
Li Shang,
Jian Cao,
Xin Song,
Bo-Shi Wang,
Yan Cai,
Qi-Min Zhan,
Ming-Rong Wang
et al.
|
Full-length article
(In Press Corrected Proof)
|
28 March 2012 |
|
Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: A potential modality for inducing long-term survival in selected patients
DOI: 10.1016/j.lungcan.2012.02.018
Abstract: Purpose: The purpose of this study was to assess the toxicity and efficacy of re-irradiation plus regional hyperthermia for recurrent NSCLC and to identify the predictors of long-term surviv...
|
Takayuki Ohguri,
Hajime Imada,
Katsuya Yahara,
Seung Dae Moon,
Shinsaku Yamaguchi,
Kazuhiro Yatera,
Hiroshi Mukae,
Takeshi Hanagiri,
Fumihiro Tanaka,
Yukunori Korogi
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 March 2012 |
|
Emphysema detected on computed tomography and risk of lung cancer: A systematic review and meta-analysis
DOI: 10.1016/j.lungcan.2012.02.019
Abstract: Background: Studies exploring the association between emphysema detected on chest computed tomography (CT) and lung cancer have yielded mixed results. Our objective was to systematically rev...
|
Benjamin M. Smith,
Lancelot Pinto,
Nicole Ezer,
Nicola Sverzellati,
Shigeo Muro,
Kevin Schwartzman
et al.
|
Full-length article
(In Press Corrected Proof)
|
22 March 2012 |
|
Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data
DOI: 10.1016/j.lungcan.2012.02.016
Abstract: While changes in heme oxygenase (HO-1) in lung cancer have already been reported, conflicting results were obtained for enzyme expression in human lung cancer specimens. Therefore, the aim o...
|
María S. Degese,
Javier E. Mendizabal,
Norberto A. Gandini,
J. Silvio Gutkind,
Alfredo Molinolo,
Stephen M. Hewitt,
Alejandro C. Curino,
Omar A. Coso,
María M. Facchinetti
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 March 2012 |
|
Retrospective study of erlotinib in patients with advanced squamous lung cancer
DOI: 10.1016/j.lungcan.2012.02.012
Abstract: Background: The effective targeted therapy for lung squamous cell carcinoma (SCC) is needed. The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The aim of this stu...
|
Jeng-Sen Tseng,
Tsung-Ying Yang,
Kun-Chieh Chen,
Kuo-Hsuan Hsu,
Hsuan-Yu Chen,
Gee-Chen Chang
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 March 2012 |
|
Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung
DOI: 10.1016/j.lungcan.2012.02.013
Abstract: Introduction: Napsin A is regarded as a marker of lung adenocarcinoma. However, no comprehensive analyses of napsin A-positive lung ADCs or the prognostic significance of napsin A expression...
|
Jin Gu Lee,
Sewha Kim,
Hyo Sup Shim
|
Full-length article
(In Press Corrected Proof)
|
15 March 2012 |
|
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group
DOI: 10.1016/j.lungcan.2012.02.002
Abstract: Introduction: Therapeutic options for patients with relapsed, chemo-resistant small-cell lung cancer (SCLC) are limited. Since paclitaxel has demonstrated single-agent activity in the second...
|
Giannis Mountzios,
Christos Emmanouilidis,
Nikolaos Vardakis,
Emmanouil Kontopodis,
Dora Hatzidaki,
Evagelos Popis,
Niki Karachaliou,
Athanassios Kotsakis,
Maria Agelidou,
Vassilis Georgoulias
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 March 2012 |
|
shRNA-mediated knockdown of Bmi-1 inhibit lung adenocarcinoma cell migration and metastasis
DOI: 10.1016/j.lungcan.2012.02.015
Abstract: Bmi-1 has been implicated in cancer cell growth and metastasis in a variety of tumor types. In this study, we sought to evaluate the expression of Bmi-1 in lung adenocarcinoma samples, and t...
|
Xiuxiang Meng,
Yifang Wang,
Xiangyu Zheng,
Chunqing Liu,
Benli Su,
Huiling Nie,
Baoxia Zhao,
Xinyu Zhao,
Hong Yang
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 March 2012 |
|
Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer
DOI: 10.1016/j.lungcan.2012.02.011
Abstract: Objective: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT) plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used cisplatin/etoposide (PE) re...
|
Luhua Wang,
Shixiu Wu,
Guangfei Ou,
Nan Bi,
Wenfeng Li,
Hua Ren,
Jianzhong Cao,
Jun Liang,
Junling Li,
Zongmei Zhou,
Jima Lv,
Xiangru Zhang
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 March 2012 |
|
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)
DOI: 10.1016/j.lungcan.2012.02.004
Abstract: Background: The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at disease progression (arm A) versus erlot...
|
H. LeCaer,
L. Greillier,
R. Corre,
H. Jullian,
J. Crequit,
L. Falchero,
C. Dujon,
H. Berard,
A. Vergnenegre,
C. Chouaid,
the GFPC 0505 Team
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 March 2012 |
|
Oncologists’ assessments of lung cancer patient and family disagreements regarding treatment decision making
DOI: 10.1016/j.lungcan.2012.02.008
Abstract: Background: Disagreements between cancer patients and their caregivers about treatment and care can affect the patient's physical and mental well-being. Therefore it is important to understa...
|
Laura A. Siminoff,
Lindsey Dorflinger,
Amma Agyemang,
Sherman Baker,
Maureen Wilson-Genderson
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 March 2012 |
|
Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy
DOI: 10.1016/j.lungcan.2012.02.006
Abstract: The expression of several cancer stem cell (CSC)-related markers has been confirmed in non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC-relat...
|
Kazuhiko Shien,
Shinichi Toyooka,
Kouichi Ichimura,
Junichi Soh,
Masashi Furukawa,
Yuho Maki,
Takayuki Muraoka,
Norimitsu Tanaka,
Tsuyoshi Ueno,
Hiroaki Asano,
Kazunori Tsukuda,
Masaomi Yamane,
Takahiro Oto,
Katsuyuki Kiura,
Shinichiro Miyoshi
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 March 2012 |